Senti Biosciences, Inc. (SNTI) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
37.48
↑+271% vs avg
5yr avg: 10.10
30Y Low0.4·High41.8
ROE
↑
-393.4%
↓+73% vs avg
5yr avg: -1459.1%
30Y Low-393%·High-62%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SNTI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Senti Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $29M | $234M | $16M | $29M | $62M | $430M | — | — |
| Enterprise Value | $41M | $246M | $1M | $31M | $41M | $397M | — | — |
| P/E Ratio → | -0.34 | — | — | — | — | — | — | — |
| P/S Ratio | 1311.65 | 10628.51 | — | 14.81 | 18.86 | 187.89 | — | — |
| P/B Ratio | 37.48 | 41.84 | 0.63 | 0.44 | 0.49 | 7.13 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SNTI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 11195.38 | — | 15.69 | 12.61 | 173.35 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
SNTI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Senti Biosciences, Inc. earns an operating margin of -289668.2%. Operating margins have compressed from -4687.9% to -289668.2% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -393.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -16431.8% | -16431.8% | — | 100.0% | 100.0% | 100.0% | 100.0% | -16987.1% |
| Operating Margin | -289668.2% | -289668.2% | — | -4687.9% | -1889.3% | -1765.4% | -6267.5% | -25625.9% |
| Net Profit Margin | -279263.6% | -279263.6% | — | -3592.4% | -1771.5% | -2414.6% | -5041.1% | -24890.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -393.4% | -393.4% | -114.1% | -73.2% | -62.0% | -6652.9% | — | -117.8% |
| ROA | -82.4% | -82.4% | -48.6% | -47.3% | -42.0% | -76.3% | -47.2% | -59.0% |
| ROIC | -328.8% | -328.8% | -114.9% | -79.3% | -69.6% | — | — | — |
| ROCE | -104.5% | -104.5% | -63.7% | -68.8% | -50.7% | -64.4% | -65.8% | -69.1% |
SNTI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $12M ($29M total debt minus $16M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 5.17 | 5.17 | 1.31 | 0.56 | 0.29 | 0.38 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 2.23 | -0.57 | 0.03 | -0.16 | -0.55 | — | -0.30 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
SNTI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.67x means Senti Biosciences, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 5.62x to 1.67x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.67 | 1.67 | 4.49 | 5.62 | 5.68 | 4.04 | 6.52 | 4.36 |
| Quick Ratio | 1.67 | 1.67 | 4.49 | 5.62 | 5.68 | 4.04 | 6.52 | 4.36 |
| Cash Ratio | 1.18 | 1.18 | 3.67 | 2.84 | 5.46 | 3.85 | 6.28 | 4.14 |
| Asset Turnover | — | 0.00 | — | 0.02 | 0.02 | 0.02 | 0.01 | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 5358.86 | — | 3266.92 | 69.53 | 76.95 | 293.67 | 334.94 |
SNTI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Senti Biosciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $225M | $5M | $4M | $4M | $4M | $4M | $1M |
Peer Comparison
Compare SNTI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SNTIYou | $29M | -0.3 | — | — | -16431.8% | -289668.2% | -393.4% | -328.8% | — |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $4B | -42.1 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 SGMO | $75M | -0.4 | — | — | 80.8% | -273.1% | -2891.8% | -5405.6% | — |
 EDIT | $263M | -1.5 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 ILMN | $25B | 29.7 | 22.7 | 26.4 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $173B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 CDNA | $1B | -65.5 | — | 37.4 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 PACB | $435M | -0.8 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
SNTI — Frequently Asked Questions
Quick answers to the most common questions about buying SNTI stock.
What is Senti Biosciences, Inc.'s P/E ratio?
Senti Biosciences, Inc.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
What is Senti Biosciences, Inc.'s ROE?
Senti Biosciences, Inc.'s return on equity (ROE) is -393.4%. The historical average is -152.1%.
Is SNTI stock overvalued?
Based on historical data, Senti Biosciences, Inc. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Senti Biosciences, Inc.'s profit margins?
Senti Biosciences, Inc. has -16431.8% gross margin and -289668.2% operating margin.